| Ref. | () ratioa | EDSS baseline | Clinical/MRI activity (≤1year) | Rituximab protocol | Biomarkers |
| [8] | 23 1.5 : 1 | 6.5 2.5-7.0 | Yes | IT LP 25 mg ×2 IV 200 mg ×2 | IgG index, NFL, CXCL13, CCL19, sCD14: unchanged; IL12p40 -42%, BAFF +8%, sCD21, sCD27: minimal changes. | [9] | 23 1 : 0 | 6.5 4.0-7.5 | No | IT Om. 25 mg ×3 | NFL, GFAP, MBP, Gal-9, sCD27, CXCL14: unchanged; CXCL13: minimal decrease. | [10] | 9 1 : 0 | 5.5 4.0-8.0 | Yes | IT LP 5-10-15 mg | λ FLC, CXCL13: unchanged; κFLC: minimal increase; BAFF: decreased | [11] | 8 1 : 0 | 6.0 | No | IT LP 25 mg ×2 | NFL, sCD21, sCD27, sCD14, CCL19, CCL21: unchanged; BAFF increased; CXCL13: decreased. | Our | 10 4 : 1 | 6.5 6.0-8.0 | No | IT LP 20 mg ±IV 375 mg/m2 (1 : 1) | IgG index, OCB, NFL, OPN: unchanged. |
|
|